Slide 1: Investors Update – Q4FY10
Investors Update – Q4FY10 • Revenues up 3% at Rs 267 crores • Net profit at Rs 0.42 crores for Q4 FY 10 against Rs 1.47 crores loss for Q4 FY09 • Domestic formulation sales up 15% at 131.43 crores • Export Formulation sales up by 13% at Rs 39.61 crores for Q4 FY10 • ORG MAT March 2010 growth of 25%
Slide 2: Management Discussion – Q4FY10
Management Discussion – Q4FY10 Alembic limited reported consolidated revenues of Rs 267 crores for the quarter ended 31st March 2010, compared to Rs 259 crores in the corresponding quarter last year. The Company posted a consolidated profit of Rs. 0.42 crores as against loss of Rs. 1.47 crores in th
Slide 3: Secondary sales growth of 25% in March 2010 MAT
Company recorded secondary sales growth of 25% in March 2010 MAT against Industry growth of 18%. The market share grew to 1.91% against 1.81% (as per ORG IMS – March 2010). There has been significant increase in market share in following therapeutic area. Mar MAT Mar MAT Therapeutic areas 10 09 Incr
Slide 4: Eyecare division sales and segment-wise growth versus industry
Within a year of launch, Eyecare, Opthalmological division, has achieved sales of Rs. 3.7 Crores. Company is still in investment mode in this therapeutic segment which has huge potential. Detailed below is segment wise comparison of industry and Alembic growth as per ORG – MAT March ‘10. (MAT Growth
Slide 5: International & API Business
¾ International & API Business Total Export sales for the third quarter were Rs 96.75 crores vis-à-vis Rs 116.88 crores in the corresponding period last year. Export formulations grew by 13% to 39.1 crores during the quarter. API business witnessed de-growth of 15% during the quarter and stood at Rs
Slide 6: Export Sales and Total Revenue; International Generics
Export Sales Total Revenue 30000 14000 Domestic Business 12000 Regulatory Sales 25000 Export Business ROW Sales 10000 R e v e n u e s in L a R e v e n u e in L a c 20000 Total Total 8000 15000 6000 10000 4000 5000 2000 0 0 Q4FY10 Q4FY09 Q4FY10 Q4FY09 International Generics Export formulations grew b
Slide 7: Interest and Foreign Exchange Losses; Buyback of Shares
API Export Sales - Region wise in % Formulations Export Sales - Regionwise in % 26% US 23% 32% Canada Europe 49% South Korea 0% Australia US/Canada 16% 1% ROW 2% Europe 51% ROW Interest and Foreign Exchange Losses: Net Interest costs during the quarter were lower at Rs. 1.19 crores on account of eff
Slide 8: Financial and Operating Result - Q4FY10
(Rs in Lacs) Financial and Operating Result - Q4FY10 Particulars Q4FY10 Q4FY09 Gr % Income from Operations 26389 25710 3% Total Expenditure 24580 24182 2% - (Increase) / decrease in stock (607) (710) - Consumption of Raw Material 10722 9390 - Consumption of Traded Goods 2981 3878 4% - Employee cost
Slide 9: Business Performance - Rs. in Lacs
Business Performance - Rs. Sales Lacs Particulars Formulations Bulk Total Q4FY10 Q4FY09 Gr % Q4FY10 Q4FY09 Gr% Q4FY10 Q4FY09 Gr % Domestic 13143 11442 15% 3871 2776 39% 17014 14218 20% Export - Regulatory 2235 2665 -16% 2248 4676 -52% 4483 7341 -39% Export - ROW 1726 827 109% 2137 1898 13% 3863 2725
Slide 10: About Company
About Company Established in 1907, Alembic Ltd. is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segm